tiprankstipranks
TipRanksTop Financial ExpertsInsidersRedmile Group, Llc

Redmile Group, Llc Insider Profile

11 Followers
Redmile Group, Llc, Ten Percent Owner at Array Biopharma, holds 12.88M shares in Fate Therapeutics (Ticker: FATE), holds 22.93M shares in ADC Therapeutics (Ticker: ADCT), holds 0.00 shares in IGM Biosciences (Ticker: IGMS).
See the Hottest Stocks Based on Insider Trading >
tipranks
Redmile Group, Llc

Redmile Group, Llc
Array Biopharma (~ARRY)
Ten Percent Owner

Ranked #9,916 out of 107,043 Corporate Insiders

Profitable Transactions

40%
18 out of 45 Profitable Transactions

Average Return

+8.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
How are Insiders Ranked?

Insider Holdings

$950M
19.62%
18.08%
15.12%
11.27%
35.90% Others
A breakdown of Redmile Group, Llc's holdings
See the Top Stocks by Insiders

Insider Roles

Amicus
(FOLD)
Ten Percent Owner
Zymeworks
(ZYME)
Ten Percent Owner
Kymera Therapeutics
(KYMR)
Ten Percent Owner
Neurogene
(NGNE)
Ten Percent Owner
+18 other positions
Roles that Redmile Group, Llc holds in companies
See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:
Fate Therapeutics
(FATE)
Rating:Informative Buy
Date:Jun 17, 2020 - Jun 17, 2021
Return:+165.20%
The most profitable trade made by Redmile Group, Llc
See the Latest Stocks Traded by Insiders

Redmile Group, Llc's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
~ARRY
Array Biopharma
Sep 30, 2016
―
Informative Sell
15.85M
$916.36M
FOLD
Amicus
Jun 13, 2016
Ten Percent Owner
Informative Buy
―
$186.39M
ALDR
Alder Biopharmaceuticals
Oct 24, 2019
―
Uninformative Sell
―
$0.00
XERS
Xeris Pharmaceuticals
Feb 21, 2019
Ten Percent Owner
Informative Buy
5.88M
$17.67M
ALLK
Allakos
Jul 24, 2018
―
Uninformative Buy
―
$331.99K
REPL
Replimune Group
Jul 25, 2018
Ten Percent Owner
Uninformative Buy
―
$1.45M
FATE
Fate Therapeutics
Apr 22, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$17.39M
GRTSQ
Gritstone bio
Oct 03, 2018
―
Uninformative Buy
―
$15.34K
VAPO
Vapotherm
Nov 16, 2018
―
Uninformative Buy
―
$2.08M
TCRR
TCR2 Therapeutics
Feb 21, 2019
―
Uninformative Buy
―
$1.19M
HOOK
Hookipa Pharma
Apr 24, 2019
Ten Percent Owner
Uninformative Buy
―
$1.14M
IGMS
IGM Biosciences
Aug 15, 2025
―
Uninformative Sell
―
$0.00
CABA
Cabaletta Bio
Oct 29, 2019
Ten Percent Owner
Uninformative Buy
―
$2.18M
APRE
Aprea Therapeutics
Feb 16, 2021
Ten Percent Owner
Informative Sell
2.79M
$1.60M
BCEL
Atreca
Jun 24, 2019
―
Uninformative Buy
―
$64.38K
AKRO
Akero Therapeutics
Jun 24, 2019
―
Uninformative Buy
―
$40.65M
STOK
Stoke Therapeutics
Jun 24, 2019
Ten Percent Owner
Uninformative Buy
―
$23.92M
BEAM
Beam Therapeutics
Feb 11, 2020
Ten Percent Owner
Uninformative Buy
―
$35.65M
NGNE
Neurogene
Apr 06, 2020
Ten Percent Owner
Informative Buy
2.01M
$107.09M
PLRX
Pliant Therapeutics
Jun 09, 2020
Ten Percent Owner
Uninformative Buy
―
$2.46M
RPTX
Repare Therapeutics
Jun 25, 2020
―
Uninformative Buy
―
$4.20M
NRIX
Nurix Therapeutics
Jul 30, 2020
Ten Percent Owner
Uninformative Buy
―
$19.34M
ANNX
Annexon Biosciences
Jul 30, 2020
Ten Percent Owner
Uninformative Buy
―
$9.90M
KLRS
Kalaris Therapeutics
Aug 05, 2020
Ten Percent Owner
Uninformative Buy
―
$5.17M
KYMR
Kymera Therapeutics
Aug 25, 2020
Ten Percent Owner
Uninformative Buy
―
$143.61M
STTK
Shattuck Labs
Dec 06, 2024
Director, Ten Percent Owner
Uninformative Buy
1.28M
$42.99M
VERV
Verve Therapeutics
Jun 23, 2021
―
Uninformative Buy
―
$21.55M
ABSI
AbSci
Jun 14, 2024
Director
Uninformative Buy
―
$32.22M
IVVD
Invivyd
Aug 12, 2021
Ten Percent Owner
Uninformative Buy
―
$5.39M
SNCE
Science 37
Mar 13, 2024
―
Uninformative Sell
5.85M
$0.00
AUGX
Augmedix
Oct 04, 2024
―
Uninformative Sell
75.40M
$0.00
TRDA
Entrada Therapeutics Inc
Nov 04, 2021
Ten Percent Owner
Uninformative Buy
―
$25.54M
MDVLQ
MedAvail Holdings
Jul 06, 2022
Director, Ten Percent Owner
Uninformative Buy
18.07M
$2.69M
ZYME
Zymeworks
Oct 17, 2022
Ten Percent Owner
Uninformative Buy
153.32K
$171.77M
RYZB
RayzeBio, Inc.
Sep 21, 2023
―
Uninformative Buy
―
$116.09M
ADCT
ADC Therapeutics
Apr 02, 2026
Ten Percent Owner
Informative Sell
19.59M
$94.25M
List of latest transactions for each holding click on a transaction to see Redmile Group, Llc's performance on stock
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Redmile Group, Llc insider profile FAQ

What is the percentage of profitable transactions made by Redmile Group, Llc?
The percentage of profitable transactions made by Redmile Group, Llc is 40%.
    What is the average return per transaction made by Redmile Group, Llc?
    The average return per transaction made by Redmile Group, Llc is 8.30%.
      What stocks does Redmile Group, Llc hold?
      Redmile Group, Llc holds: ~ARRY, FOLD, ALDR, XERS, ALLK, REPL, FATE, GRTSQ, VAPO, TCRR, HOOK, IGMS, CABA, APRE, BCEL, AKRO, STOK, BEAM, NGNE, PLRX, RPTX, NRIX, ANNX, KLRS, KYMR, STTK, VERV, ABSI, IVVD, SNCE, AUGX, TRDA, MDVLQ, ZYME, RYZB, ADCT stocks.
        What was Redmile Group, Llc’s latest transaction?
        Redmile Group, Llc latest transaction was an Uninformative Buy of ―.
          What was Redmile Group, Llc's most profitable transaction?
          Redmile Group, Llc’s most profitable transaction was an Informative Buy of FATE stock on June 17, 2020. The return on the trade was 165.20%.
            What is Redmile Group, Llc's role in Array Biopharma?
            Redmile Group, Llc's role in Array Biopharma is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.